BridgeBio Pharma Inc Topline Results Transcript
Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's topline 30-month results from the Phase III ATTRibute-CM study in patients with transthyretin amyloid cardiomyopathy. (Operator Instructions). Please be advised that today's conference is being recorded.
I would now like to introduce you to the speakers today. Jonathan Fox, MD, PhD, Chief Medical Officer of BridgeBio Cardiorenal; Uma Sinha, PhD, Chief Scientific Officer of BridgeBio; Matt Outten, MBA, ALM CPC, Chief Commercial Officer of BridgeBio.
I will now hand it over to Neil Kumar, CEO of BridgeBio.
Thank you, operator, and thanks, everyone, for joining this call. I'm grateful to be able to share with you on behalf of the extraordinary physicians, patients, families and caregivers involved the positive Phase III results of our ATTRibute cardiomyopathy clinical trial. The strongly positive and consistent data the community worked tirelessly to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |